Literature DB >> 19023192

Clinical course of pulmonary embolism in lung cancer patients.

Jung-Woo Lee1, Seung-Ick Cha, Chi-Young Jung, Won-Il Choi, Kyung-Nyeo Jeon, Seung-Soo Yoo, Chang-Ho Kim, Jae-Yong Park, Tae-Hoon Jung.   

Abstract

BACKGROUND: Although lung cancer is the most common malignancy diagnosed in patients with venous thromboembolism (VTE), data regarding pulmonary embolism (PE) in lung cancer patients are limited.
OBJECTIVES: To investigate the clinicoradiological features, clinical course and survival of lung cancer patients with PE.
METHODS: We performed a retrospective case-control study investigating the clinical course and survival of 40 lung cancer patients with PE (PE group). The control group (non-PE group) consisted of 80 lung cancer patients without VTE, treated during the same period.
RESULTS: Adenocarcinoma (45.0%, n = 18) was the most common histological type of lung cancer and when PE was diagnosed, the majority of the lung cancer patients were in stages IIIB (37.5%, n = 15) and IV (47.5%, n = 19). Thirty-four patients (85.0%) were diagnosed with PE within 12 months of the diagnosis of lung cancer. The median survival from the diagnosis of PE was 3.5 months in the PE group, but the survival rates revealed no significant difference between the two groups (p = 0.249). In both groups, the most common cause of death was lung cancer progression (76.9 and 80.3%, respectively), followed by chemotherapy-related septic shock (19.2 and 16.7%, respectively).
CONCLUSIONS: In lung cancer patients, PE may not be the main cause of death, but one of the various complications of lung cancer, despite suggesting a poor prognosis. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2008        PMID: 19023192     DOI: 10.1159/000176208

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  8 in total

1.  Comorbidity assessment as predictor of short and long-term mortality in elderly patients with hemodynamically stable acute pulmonary embolism.

Authors:  Hernan Polo Friz; Valeria Corno; Annalisa Orenti; Chiara Buzzini; Chiara Crivellari; Francesco Petri; Melisa Polo Friz; Veronica Punzi; Daniela Teruzzi; Luca Cavalieri d'Oro; Cristina Giannattasio; Giuseppe Vighi; Claudio Cimminiello; Patrizia Boracchi
Journal:  J Thromb Thrombolysis       Date:  2017-10       Impact factor: 2.300

2.  LUNG CANCER AND PULMONARY THROMBOEMBOLISM.

Authors:  Vesna Cukic; Aida Ustamujic
Journal:  Mater Sociomed       Date:  2015-10-05

Review 3.  Imaging of urgencies and emergencies in the lung cancer patient.

Authors:  Bruno De Potter; Jef Huyskens; Birgitta Hiddinga; Maarten Spinhoven; Annelies Janssens; Jan P van Meerbeeck; Paul M Parizel; Annemie Snoeckx
Journal:  Insights Imaging       Date:  2018-04-11

Review 4.  Lung Cancer and Pulmonary Embolism: What Is the Relationship? A Review.

Authors:  Yupeng Li; Yu Shang; Wenwen Wang; Shangwei Ning; Hong Chen
Journal:  J Cancer       Date:  2018-08-06       Impact factor: 4.207

5.  Clinical features of pulmonary embolism in patients with lung cancer: A meta-analysis.

Authors:  Xin Hua; Shu-Hua Han; Shu-Zhen Wei; Ying Wu; Jun Sha; Xiao-Li Zhu
Journal:  PLoS One       Date:  2019-09-30       Impact factor: 3.240

6.  Pulmonary embolism concurrent with lung cancer and central emboli predict mortality in patients with lung cancer and pulmonary embolism.

Authors:  Seung-Ick Cha; Kyung-Min Shin; Jae-Kwang Lim; Seung-Soo Yoo; Shin-Yup Lee; Jaehee Lee; Chang-Ho Kim; Jae-Yong Park; Won-Kee Lee; Chi-Young Jung
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

7.  Clinical relevance of bronchial anthracofibrosis in patients with chronic obstructive pulmonary disease exacerbation.

Authors:  Hyera Kim; Seung-Ick Cha; Kyung-Min Shin; Jae-Kwang Lim; Serim Oh; Min Jung Kim; Yong Dae Lee; Miyoung Kim; Jaehee Lee; Chang-Ho Kim
Journal:  Tuberc Respir Dis (Seoul)       Date:  2014-09-30

8.  Lung Cancer Complicated With Asymptomatic Pulmonary Embolism: Clinical Analysis of 84 Patients.

Authors:  Guangsheng Li; Yuechuan Li; Shuping Ma
Journal:  Technol Cancer Res Treat       Date:  2017-11-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.